Moderna jumps on Oppenheimer upgrade, 2025 sales growth goal

According to Oppenheimer, Moderna could have five products on the market by 2026.

Moderna shares fell 29% in 2022 after they more than doubled in 2021. The stock had tracked a fivefold increase in 2020.

The stock was among the biggest gainers on the S&P 500 Healthcare index on Tuesday.

Bancel reiterated the company's goal to break even in 2026 as revenue grows and research and development costs for late-stage candidates recede.

Moderna had previously said it expects $4 billion in revenue in 2024 from the sale of its COVID and RSV vaccines.

Bancel recently took over the responsibility to oversee sales and marketing of vaccine after Arpa Garay stepped down as the chief commercial officer.

Moderna had said in November it would only hit the low end of its sales forecast of $6 billion to $8 billion for 2023, reflecting weaker demand for COVID vaccines.

Moderna's price to tangible book value ratio, a common benchmark for valuing stocks, stood at 2.84 compared with 1.21 for rival BioNtech .

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-surges-after-ceo-says-sales-growth-expected-2025-2024-01-02/#:~:text=Moderna%20jumps%20on%20Oppenheimer%20upgrade%2C%202025%20sales%20growth%20goal,-By%20Reuters&text=Jan%202%20(Reuters)%20%2D%20Moderna,achieving%20sales%20growth%20in%202025.